C
Cagricema
Productby Novo Nordisk
Heard in 1 episode across 1 show since Sep 2026
CagriSema is an investigational once-weekly fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being developed to support weight management and treatment of type 2 diabetes by reducing body weight and improving glycemic control.
Episodes
1
across 1 show
First heard
Sep 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 0 |
Episodes
1 episode featuring Cagricema, newest first
